Microfibril-associated glycoproteins attenuating pulmonary fibrosis
微纤维相关糖蛋白减轻肺纤维化
基本信息
- 批准号:10595656
- 负责人:
- 金额:$ 15.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdvisory CommitteesAffinityAttenuatedBindingBioinformaticsBiological AssayBiologyBleomycinBone MarrowCell NucleusCellsCharacteristicsChromatinCollaborationsCompensationDataDepositionDevelopmentDiseaseDisease ProgressionExhibitsExtracellular MatrixFamily memberFibroblastsFibrosisFollow-Up StudiesGene ExpressionGene Expression RegulationGenesGlycoproteinsGoalsGrowth FactorHomeostasisHumanHypoxiaImageImmuneImmune responseIn SituIndividualInflammatoryInflammatory Response PathwayInjuryInterstitial Lung DiseasesKnock-outKnockout MiceLungLung TransplantationLung diseasesMFAP1 geneMacrophageMediatingMentorsMesenchymalMicrofibrilsModelingMusNamesPathogenesisPathway interactionsPhasePhenotypePhysiciansPlayPopulationProcessProductionProliferatingProtein SecretionProteinsPulmonary FibrosisRecoveryRegulationReportingResearch PersonnelRoleScientistSignal TransductionSpecificitySupportive careTissuesTrainingTransforming Growth Factor betaTransposaseUp-RegulationWorkairway obstructionantifibrotic treatmentcareercareer developmentcytokineepigenomeepigenomicsexperimental studyfibrogenesisfibrotic lungidiopathic pulmonary fibrosisimmune cell infiltrateimmune functionimprovedin vivoinhibitorinterestlung histologylung injurymortalitynovel strategiesreceptorresponseside effectsingle cell sequencingsingle nucleus RNA-sequencingsingle-cell RNA sequencingtranscriptometranscriptome sequencingtranscriptomicstransforming growth factor beta3
项目摘要
Project Summary/Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options and unclear
pathogenesis. Extracellular matrix (ECM) deposition by proliferating fibroblast populations drives the
progressive airflow limitation and hypoxia characteristic of IPF, mediated by the cytokine transforming growth
factor beta (TGFB). Direct inhibition of TGFB leads to intolerable side effects, and there is increased interest in
therapies that instead modulate its regulation. Microfibril-associated glycoproteins 1 and 2 (Magp1 and Magp2,
or Magps) are fibroblast-produced proteins which are secreted to ECM, anchor to microfibrils, and bind TGFB
to limit its signaling under basal conditions, but have no known role in fibrosis. Magp knockout (KO) mice
exhibit increased TGFB signaling in various tissues and have immune cell alterations due to bone marrow
TGFB effects. In a single cell RNASeq screen, the genes encoding these proteins were markedly upregulated
in fibroblasts in fibrotic lungs, and combined KO of Magp1 and 2 led to more severe fibrosis after bleomycin
injury in mice. This suggests that Magps act as inhibitors of fibrotic signaling and follow up studies in Magp1
and 2 individual KO mice show that deficiency of both proteins is required to produce a pro-fibrotic phenotype.
Which fibroblasts populations produce Magps and how they limit fibrosis is unknown. We hypothesize that
Magp expression is an adaptive response to lung injury and limits fibrosis by sequestering TGFB in ECM and
will explore this central hypothesis through three specific aims: 1) Evaluate anti-fibrotic contributions of
Magp1 and 2 in pulmonary fibrosis. 2) Evaluate Magp effects on TGFB signaling and immune
responses in lung fibrosis. 3) Characterize Magp-producing fibroblast populations. Using combinations
of KO and inducible/tissue-specific KO mice, we will determine the individual relationships of these proteins to
fibrosis and whether they exhibit redundant antifibrotic functions in vivo. We will analyze alterations in TGFB
signaling and immune cell infiltration in lung as possible underlying mechanisms of Magp protection from
pulmonary fibrosis. Finally, we will employ our recently developed single nucleus RNASeq approach along with
single nucleus assay for transposase-accessible chromatin (snATAC)-Seq to characterize the fibroblast
populations that express Magp1 and 2 and evaluate how lung-wide transcriptomes and epigenomes change in
the absence of Magps during fibrosis. This proposal will provide Dr. Koenitzer with the mentored training in
single cell sequencing and bioinformatics, fibroblast and ECM biology, and lung histology/imaging needed to
achieve his goal of independence as a physician-scientist. Under the oversight of an expert scientific advisory
committee, He will realize career milestones, complete formal coursework, and develop lasting collaborations.
Findings from this work will have implications beyond IPF in other interstitial lung diseases and enable Dr.
Koenitzer to develop new approaches to the treatment of lung disease as an independent investigator.
项目总结/摘要
特发性肺纤维化(IPF)是一种进行性肺部疾病,治疗选择有限且尚不清楚
发病机制细胞外基质(ECM)沉积的增殖成纤维细胞群体驱动的,
IPF的进行性气流受限和缺氧特征,由细胞因子转化生长介导
因子β(TGFB)。TGFB的直接抑制导致不可耐受的副作用,并且对TGFB的直接抑制的兴趣增加。
而不是调节其调节的疗法。微纤维相关糖蛋白1和2(Magp 1和Magp 2,
或Magps)是成纤维细胞产生的蛋白质,其分泌到ECM,锚于微纤维,并结合TGFB
以限制其在基础条件下的信号传导,但在纤维化中没有已知的作用。Magp敲除(KO)小鼠
在各种组织中表现出增加的TGFB信号传导,并且由于骨髓炎而具有免疫细胞改变。
TGFB效应。在单细胞RNASeq筛选中,编码这些蛋白质的基因显著上调,
在纤维化肺的成纤维细胞中,Magp 1和2的联合KO导致博来霉素治疗后更严重的纤维化。
小鼠损伤。这表明Magps可作为纤维化信号传导的抑制剂,并对Magp 1进行了后续研究。
和2个单独的KO小鼠显示,两种蛋白质的缺陷是产生促纤维化表型所必需的。
哪些成纤维细胞群体产生Magps以及它们如何限制纤维化尚不清楚。我们假设
Magp表达是对肺损伤的适应性反应,并通过在ECM中隔离TGFB来限制纤维化,
将通过三个具体目标探索这一中心假设:1)评价抗纤维化的贡献
肺纤维化中的Magp 1和Magp 2 2)评估Magp对TGFB信号传导和免疫的影响
肺纤维化的反应。3)表征产生Magp的成纤维细胞群。使用组合
KO和诱导型/组织特异性KO小鼠,我们将确定这些蛋白质与
纤维化以及它们是否在体内表现出多余的抗纤维化功能。我们将分析TGFB的改变
肺中的信号传导和免疫细胞浸润可能是Magp保护
肺纤维化最后,我们将使用我们最近开发的单核RNASeq方法,沿着
转座酶可及染色质单核测定(snATAC)-Seq,用于表征成纤维细胞
表达Magp 1和2的人群,并评估肺范围内的转录组和表观基因组在
在纤维化过程中没有Magps。该提案将为Koenitzer博士提供以下方面的指导培训:
单细胞测序和生物信息学,成纤维细胞和ECM生物学,以及肺组织学/成像,
实现他作为一名医生兼科学家的独立目标。在专家科学顾问的监督下
他将实现职业生涯的里程碑,完成正式的课程,并发展持久的合作。
这项工作的发现将对IPF以外的其他间质性肺疾病产生影响,并使Dr。
Koenitzer作为独立研究者开发治疗肺部疾病的新方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey Koenitzer其他文献
Jeffrey Koenitzer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey Koenitzer', 18)}}的其他基金
Microfibril-associated glycoproteins attenuating pulmonary fibrosis
微纤维相关糖蛋白减轻肺纤维化
- 批准号:
10449885 - 财政年份:2022
- 资助金额:
$ 15.62万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 15.62万 - 项目类别:
Standard Grant